echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Bayer/Zhiben larotrectinib companion diagnostic reagent passed special review for innovative medical devices

    Bayer/Zhiben larotrectinib companion diagnostic reagent passed special review for innovative medical devices

    • Last Update: 2021-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 22, Zhiben Medical announced that the human NTRK1/2/3 gene mutation detection kit (reversible terminal termination sequencing method) has been awarded the "Special Review of Innovative Medical Devices" by the Medical Device Technology Evaluation Center of the State Drug Administration


    The human NTRK1/2/3 gene mutation detection kit (reversible terminal termination sequencing method) will be used for the detection of NTRK 1, 2, 3 gene fusion mutations in solid tumors


    Larotrectinib is a highly selective TRK inhibitor designed for the treatment of tumor patients with NTRK gene fusion.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.